rss
J Med Genet 2009;46:455-457 doi:10.1136/jmg.2008.065086
  • Short report

Functional evidence implicating FOXL2 in non-syndromic premature ovarian failure and in the regulation of the transcription factor OSR2

  1. P Laissue1,2,3,
  2. B Lakhal4,
  3. B A Benayoun1,2,3,5,
  4. A Dipietromaria1,2,3,
  5. R Braham6,
  6. H Elghezal4,
  7. P Philibert7,8,
  8. A Saâd4,
  9. C Sultan7,8,
  10. M Fellous1,2,3,
  11. R A Veitia1,2,3,5
  1. 1
    INSERM U567, Institut Cochin, Paris, France
  2. 2
    CNRS, UMR 8104, Institut Cochin, Paris, France
  3. 3
    Université Paris Descartes, Paris, France
  4. 4
    Department of Cytogenetics and Reproductive Biology, Farhat Hached University Teaching Hospital, Sousse, Tunisia
  5. 5
    Université Paris Diderot, Paris, France
  6. 6
    Department of Endocrinology, Farhat Hached University Teaching Hospital, Sousse, Tunisia
  7. 7
    Unité d’Endocrinologie-Gynécologie Pédiatrique, Service de Pédiatrie, Hôpital Arnaud-de-Villeneuve and Service d’Hormonologie du Développement et de la Reproduction, Hôpital Lapeyronie, Centre Hospitalier Universitaire Montpellier, Montpellier, France
  8. 8
    Institut de Génétique Humaine, Centre Nationale de la Recherche Scientifique UPR1142, Montpellier, France
  1. Reiner A Veitia, reiner.veitia{at}inserm.fr
  • Received 28 November 2008
  • Revised 10 February 2009
  • Accepted 23 February 2009
  • Published Online First 7 May 2009

Abstract

Background: FOXL2 encodes a forkhead transcription factor whose mutations are responsible for the blepharophimosis-ptosis-epicanthus inversus syndrome (BPES), involving craniofacial/palpebral abnormalities often associated with premature ovarian failure (POF).

Results: We describe a FOXL2 variant (p.Gly187Asp) in a case of POF without BPES. The subcellular localisation of FOXL2-G187D was normal but its transactivation capacity tested on two reporter promoters, one of which should be relevant to the ovary, was significantly lower than that of normal FOXL2. However, FOXL2-G187D was able to activate strongly a reporter construct driven by the promoter of Osr2 (odd-skipped related 2 transcription factor), which we have suggested to be a crucial target of FOXL2 in the craniofacial region. This is compatible with the absence of BPES in our patient.

Conclusions: Our data provide evidence in favour of the implication of FOXL2 variants in non-syndromic POF and confirm the regulatory interaction between FOXL2 and OSR2 whose perturbation might contribute to the palpebral abnormalities observed in BPES patients.

Footnotes

  • PL and BL contributed equally to this work

  • Funding: Our work is supported by the INSERM, the CNRS, the Université Paris-Diderot/Paris VII, the Fondation pour la Recherche Médicale (FRM), a project GIS-maladies rares and the Institut Universitaire de France (IUF).

  • Competing interests: None declared.

  • Patient consent: Obtained.

Register for free content


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JMG.
View free sample issue >>

Free archive
The full back archive is now available for JMG. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
Register to access the free archive >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

  • Latest genetics jobs

    Latest genetics jobs